Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (181-190 of 254) with videos related to

Pageof 26
Sort By:
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
JAMA Cardiology|February 14, 2024
Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention PopulationsAeron M Small, Ashley Pournamdari, Giorgio E M Melloni, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 20, 2007
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuriaHiddo Lambers Heerspink, Tom Greene, Julia B Lewis, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Diabetes Care|April 24, 2020
Adolescent Obesity and Early-Onset Type 2 DiabetesGilad Twig, Inbar Zucker, Arnon Afek, et al.
Diabetes Care|August 9, 2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 DiabetesFilipe A Moura, David D Berg, Andrea Bellavia, et al.
JAMA Cardiology|July 20, 2022
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Diabetes/Metabolism Research and Reviews|September 23, 2009
Challenges in developing endpoints for type 1 diabetes intervention studiesSimona Cernea, Itamar Raz, Kevan C Herold, et al.
Nature Reviews. Disease Primers|May 19, 2016
Type 2 diabetes mellitusRalph A DeFronzo, Ele Ferrannini, Leif Groop, et al.
Pageof 26

Showing results (181-190 of 254) with videos related to

Sort By:
Pageof 26
JAMA Cardiology|September 30, 2016
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical TrialBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|March 12, 2015
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trialLawrence A Leiter, Hwee Teoh, Eugene Braunwald, et al.
JAMA Cardiology|February 14, 2024
Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention PopulationsAeron M Small, Ashley Pournamdari, Giorgio E M Melloni, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 20, 2007
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuriaHiddo Lambers Heerspink, Tom Greene, Julia B Lewis, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Diabetes Care|April 24, 2020
Adolescent Obesity and Early-Onset Type 2 DiabetesGilad Twig, Inbar Zucker, Arnon Afek, et al.
Diabetes Care|August 9, 2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 DiabetesFilipe A Moura, David D Berg, Andrea Bellavia, et al.
JAMA Cardiology|July 20, 2022
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Diabetes/Metabolism Research and Reviews|September 23, 2009
Challenges in developing endpoints for type 1 diabetes intervention studiesSimona Cernea, Itamar Raz, Kevan C Herold, et al.
Nature Reviews. Disease Primers|May 19, 2016
Type 2 diabetes mellitusRalph A DeFronzo, Ele Ferrannini, Leif Groop, et al.
Pageof 26